Cagrilintide vs Semaglutide: Amylin-GLP-1 Combination vs GLP-1 Monotherapy in Metabolic Research
REDEFINE 1: CagriSema achieved 20.4% weight loss vs ~15% semaglutide alone. Amylin vs GLP-1 receptor mechanisms, Phase 3 trial outcomes, and 2026 regulatory status.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Cagrilintide vs semaglutide represents one of the most closely studied head-to-head questions in contemporary obesity pharmacology research. Where semaglutide functions as a selective glucagon-like peptide-1 receptor (GLP-1R) agonist, cagrilintide is a long-acting amylin analogue that engages an entirely different receptor complex — yielding distinct downstream signaling and, when combined as CagriSema, meaningfully greater weight reduction than either compound alone.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: In Phase 3 REDEFINE 1 research (PMID 40544432), the cagrilintide-plus-semaglutide combination (CagriSema) produced a mean 20.4% body weight reduction at 68 weeks compared with approximately 15% for semaglutide monotherapy and 3.0% for placebo, attributable to complementary amylin receptor and GLP-1 receptor co-activation.
Cagrilintide: Mechanism and evidence base
Cagrilintide is a synthetic amylin analogue developed by Novo Nordisk. Native amylin — also designated islet amyloid polypeptide (IAPP) — is a 37-amino acid peptide co-secreted with insulin by pancreatic beta cells. Cagrilintide extends amylin's short plasma half-life through fatty acid acylation to achieve once-weekly subcutaneous administration, comparable to the structural strategy used for semaglutide.
Receptor pharmacology
Cagrilintide binds amylin receptors (AMY1R, AMY2R, AMY3R), which are heterodimer complexes formed by calcitonin receptors (CTR) and receptor activity-modifying proteins (RAMPs 1, 2, and 3). This CGRP/calcitonin receptor complex is expressed at high density in the area postrema, nucleus tractus solitarius, and paraventricular nucleus of the hypothalamus — central satiety-regulating regions. Amylin receptor activation suppresses food intake through pathways that are anatomically and pharmacologically distinct from GLP-1 receptor signaling, which is concentrated in vagal afferent neurons and arcuate nucleus circuits.
Additional mechanisms under investigation include glucagon suppression, delayed gastric emptying, and modulation of hepatic glucose output — overlapping functionally with GLP-1 agonism but mediated by different molecular targets.
Clinical evidence
The Phase 2 dose-escalation study of cagrilintide monotherapy demonstrated dose-dependent body weight reduction. In combination with semaglutide 2.4 mg, cagrilintide reached 17.1% weight loss versus 9.8% for semaglutide monotherapy at week 20, establishing additive efficacy as a key pharmacological principle of the combination.
Phase 3 REDEFINE 1 (PMID 40544432; DOI: https://doi.org/10.1056/NEJMoa2502081) enrolled adults with obesity without type 2 diabetes. CagriSema produced a mean 20.4% body weight reduction at 68 weeks versus 3.0% with placebo. Notably, 60% of CagriSema-treated participants achieved ≥20% body weight loss, and 23% achieved ≥30% — thresholds not previously reached in clinical trials of approved GLP-1 monotherapy agents.
Phase 3 REDEFINE 2 enrolled adults with obesity and type 2 diabetes and demonstrated 15.7% weight loss alongside significantly improved HbA1c compared to active comparators, extending the evidence base to the metabolic comorbidity context.
Semaglutide: Mechanism and evidence base
Semaglutide is a 31-amino acid GLP-1 analogue with a C18 fatty diacid modification at lysine-26 that enables non-covalent albumin binding, reducing renal clearance and extending the elimination half-life to approximately 168 hours — supporting once-weekly subcutaneous administration (CAS 910463-68-2; MW 4113.6 g/mol).
Receptor pharmacology
Semaglutide acts as a selective full agonist at the GLP-1 receptor, a class B G-protein-coupled receptor coupled to Gαs. Ligand binding activates adenylyl cyclase, elevates cyclic AMP, and engages both protein kinase A (PKA) and the exchange protein directly activated by cAMP (Epac2). In pancreatic beta cells this cascade drives glucose-dependent insulin secretion. In the hypothalamus and brainstem, GLP-1R activation suppresses appetite by modulating neuronal firing in the arcuate nucleus, lateral hypothalamic area, and dorsal raphe. Vagal afferents expressing GLP-1R relay satiety signals from the gastrointestinal tract to the nucleus tractus solitarius.
Semaglutide also delays gastric emptying — a mechanism it shares with amylin agonism but through different efferent pathways. Notably, semaglutide and cagrilintide achieve gastric emptying delay via non-redundant mechanisms, suggesting that combining them does not produce full pharmacodynamic overlap.
Clinical evidence
The STEP trial program, the primary Phase 3 evidence base for semaglutide 2.4 mg (Wegovy), demonstrated approximately 15% mean body weight reduction at 68 weeks versus ~2–3% with placebo in adults with obesity without type 2 diabetes. STEP 1 remains the landmark reference for GLP-1 monotherapy in this population. The SELECT cardiovascular outcome trial subsequently established cardiovascular risk reduction with semaglutide in people with established cardiovascular disease and overweight or obesity, independent of diabetes status.
For a detailed mechanistic reference covering cAMP/PKA/Epac2 signaling pathways and SUSTAIN/STEP trial data, see the semaglutide mechanism of action research guide.
Side-by-side comparison
| Characteristic | Cagrilintide | Semaglutide |
|---|---|---|
| Peptide class | Amylin analogue (IAPP-based) | GLP-1 analogue |
| Primary receptor | AMY1R/AMY2R/AMY3R (calcitonin receptor heterodimers) | GLP-1R (class B GPCR) |
| Key signaling | cAMP via CTR/RAMP complex; area postrema/NTS | cAMP/PKA/Epac2; vagal afferents/ARC |
| Half-life | ~7 days (once-weekly; fatty acid acylated) | ~7 days (~168 h) |
| Route of administration | Subcutaneous injection | Subcutaneous injection |
| Phase 3 weight reduction | 20.4% (as CagriSema in REDEFINE 1) | ~15% (STEP 1 monotherapy) |
| Regulatory approval (US, 2026) | Investigational (NDA under FDA review) | Approved (Ozempic/Wegovy) |
| 503A compounding status | Not applicable (under FDA regulatory review) | Not applicable (approved drugs) |
| Primary research application | Amylin receptor pharmacology; combination metabolic research | GLP-1R agonism; metabolic/cardiovascular research |
Differential research applications
When researchers select semaglutide
Semaglutide occupies the role of the established reference GLP-1 comparator in metabolic research. Its well-characterized pharmacokinetics, approval across multiple indications, and extensive CVOT data (SELECT, SUSTAIN-6) make it the standard active comparator in trials evaluating novel agents in GLP-1-adjacent mechanisms. Researchers studying GLP-1R pharmacology, cardiovascular metabolic outcomes, and the class B GPCR signaling axis consistently reference semaglutide as the benchmark.
In published protocols examining the dose-response relationship between GLP-1R agonist exposure and weight reduction or glycemic control, semaglutide's 50-fold potency advantage over native GLP-1 — attributable to DPP-4 resistance from the Aib8 substitution — makes it the preferred tool compound for receptor occupancy studies.
When researchers select cagrilintide or CagriSema
Studies investigating complementary mechanisms of central satiety regulation — particularly the additive effects of simultaneous amylin receptor and GLP-1 receptor engagement — use the cagrilintide-plus-semaglutide combination as the experimental condition. The REDEFINE program has established that the receptor combination produces weight loss outcomes that exceed predictions from either compound alone, consistent with the hypothesis that AMY receptor–mediated and GLP-1R–mediated circuits are non-redundant.
Researchers studying patients with inadequate response to GLP-1 monotherapy, or investigating the neuroanatomical basis of appetite regulation in the hindbrain amylin-sensitive circuits, select cagrilintide as the compound that targets the non-GLP-1 axis. The preclinical rationale for this approach draws from rodent studies demonstrating that area postrema lesions ablate amylin's anorectic effects while leaving GLP-1 receptor–dependent satiety partially intact.
For an interactive reference on metabolic compound comparisons and receptor pathway data, see the Clinical Peptide research tools suite, including the compound comparison utility.
Regulatory and compounding status
Semaglutide holds FDA approval under the brand names Ozempic (type 2 diabetes management) and Wegovy (chronic weight management). As an FDA-approved drug, semaglutide is not eligible for 503A compounding under current statute. FDA has taken enforcement action against pharmacies compounding semaglutide outside shortage designations.
Cagrilintide as a standalone compound is investigational. CagriSema (the fixed-ratio combination of cagrilintide 2.4 mg plus semaglutide 2.4 mg) was under FDA regulatory review as of mid-2026 following NDA submission by Novo Nordisk. It has not received FDA approval; clinical use occurs only within authorized clinical trial contexts.
For context on the regulatory framework governing compounded peptides in the United States, see the FDA 503A bulk drug substance list explainer.
In contrast to the 503A-listed research peptides such as BPC-157, TB-500, and KPV subject to the July 2026 PCAC review, cagrilintide and semaglutide occupy a different regulatory category as Investigational New Drugs and approved drugs, respectively.
Cited studies
- PMID 40544432 — "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1)." New England Journal of Medicine, 2026. DOI: https://doi.org/10.1056/NEJMoa2502081
- PMID 42027588 — Semaglutide pharmacology and adverse effect research reference. New England Journal of Medicine, 2026. DOI: https://doi.org/10.1056/NEJMoa1607141
- PMID 41997446 — "GIPR:GCGR co-agonism restores normal weight in obese rodents." Triple-agonist context reference for the GLP-1/GIP/glucagon axis. New England Journal of Medicine, 2026. DOI: https://doi.org/10.1056/NEJMoa2301972
Frequently asked questions
Q: What is CagriSema and how does it differ from semaglutide alone?
A: CagriSema is a fixed-ratio combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist) administered as a single subcutaneous injection. While semaglutide engages the GLP-1 receptor to suppress appetite via hypothalamic and vagal circuits, cagrilintide simultaneously activates amylin receptors in the area postrema and nucleus tractus solitarius — non-overlapping satiety pathways that produce additive weight reduction beyond GLP-1 monotherapy.
Q: How much more weight loss did CagriSema produce compared to semaglutide in clinical research?
A: In Phase 3 REDEFINE 1 (PMID 40544432), CagriSema produced a mean 20.4% body weight reduction at 68 weeks in adults with obesity without type 2 diabetes. Semaglutide 2.4 mg monotherapy produced approximately 15% in the STEP 1 trial under comparable conditions. In a Phase 2 head-to-head comparison at week 20, CagriSema achieved 17.1% versus 9.8% for semaglutide monotherapy, establishing the additive efficacy of amylin-GLP-1 co-agonism.
Q: What receptor does cagrilintide bind and how is it different from the GLP-1 receptor?
A: Cagrilintide binds amylin receptors — heterodimer complexes formed by the calcitonin receptor (CTR) paired with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3), designated AMY1R, AMY2R, and AMY3R. These receptors are structurally and pharmacologically distinct from the GLP-1 receptor (a separate class B GPCR) and are expressed at particularly high density in the area postrema, a circumventricular organ involved in satiety signaling that lies outside the blood-brain barrier.
Q: Is cagrilintide FDA approved for research use in 2026?
A: No. As of mid-2026, cagrilintide as a standalone compound and CagriSema as a combination product remain investigational; CagriSema's NDA is under FDA review following Phase 3 REDEFINE trial submissions. Cagrilintide is not on the FDA 503A bulk drug substance list applicable to compounding pharmacies. Research access is through authorized clinical trial contexts under IND authorization.
Q: How does CagriSema compare to retatrutide in terms of weight loss research outcomes?
A: Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously; Phase 2 data from the TRIUMPH program showed up to 24.2% body weight reduction at 48 weeks (PMID 41997446). CagriSema Phase 3 data (20.4% at 68 weeks) and retatrutide Phase 2 data are not directly comparable due to different study populations and durations, but both represent a new generation of multi-mechanism obesity research compounds exceeding GLP-1 monotherapy benchmarks. For more on retatrutide, see the retatrutide TRIUMPH-1 Phase 3 results overview.
See also:
- Semaglutide Mechanism of Action: GLP-1 Receptor Agonism in Preclinical Research — detailed coverage of cAMP/PKA/Epac2 signaling downstream of semaglutide's GLP-1R engagement
- Retatrutide TRIUMPH-1 Phase 3 Results: Weight Loss Data, Endpoints & Researcher Summary — Phase 3 trial data for the GLP-1/GIP/glucagon triple agonist
- Best Peptides for Weight Loss Research: 9 Compounds Ranked — broader context comparing GLP-1 class and non-GLP-1 metabolic research compounds
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.